Avastin/FOLFIRI in Combination With Curcumin in Colorectal Cancer Patients With Unresectable Metastasis
First Line Avastin/FOLFIRI in Combination With Curcumin-containing Supplement in Colorectal Cancer Patients With Unresectable Metastasis
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age : 20 Years and older
- Histologically confirmed adenocarcinoma of the colon or rectum
- Patients with primary colon or rectal cancer and unresectable metastatic lesions.
- Patients with no primary cancer related symptoms.
- ECOG performance status of 0 - 2
- Appropriate organ functions (hepatic transaminases - less than 5 times the normal range; bilirubin - less than 2 times the normal range; creatinine serum - less than 1.5 times the normal range; thrombocyte - more than 100,000/µl; neutrophil - more than 1,500/µl)
- ASA score of < 3
- An informed consent form has been signed by the patient.
Exclusion Criteria:
- Colorectal cancer other than adenocarcinoma
- The patient received adjuvant chemotherapy within the past 6 months.
- The patient received chemotherapy for metastatic colon cancer.
- The patient was planning to have curative surgery for the metastatic lesions.
- Patients with peritoneal carcinomatosis.
- Patients with primary tumor related complications such as intestinal obstruction, intractable bleeding, and perforation, that needs to be treated.
- ASA score of > 4
- The patient has chronic hepatitis or cirrhosis. An asymptomatic HBV or HCV carrier can participate.
- Patients with an active infection, which need antibiotic therapy, during the randomization period.
- Pregnant or breastfeeding women
- Patients with another different malignant tumor during the past 5 years. Patients with treated non-melanoma skin cancer or cervical cancer can be enrolled in this study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Avastin/FOLFIRI with curcumin
Patients will receive first line Avastin/FOLFIRI in combination with curcumin-containing supplement
|
Avastin: 5mg/kg iv on day1, every 14 days.
Irinotecan: 180 mg /m2 iv on day1, every 14 days.
Leucovorin: 200 mg/m2 iv on day1,2 every 14 days.
5-fluorouracil bolus: 400 mg/m2 iv on day1,2 every 14 days.
5-fluorouracil infusion: 1200 mg/m2 iv on day1,2 every 14 days.
Other Names:
Dietary supplement of nanostructured lipid curcumin particle 100mg po bid daily
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Progression-free survival
Time Frame: 2 years
|
The primary end point of this study is to evaluate progression-free survival in colorectal cancer patients with unresectable metastasis after treatment with first line Avastin/FOLFIRI in combination with a dietary supplement of nanostructured lipid curcumin particle (Aju Pharm, Korea), which improved biotransformation and bioavailability profiles of curcumin.
|
2 years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Overall survival rate
Time Frame: 3 years
|
Overall survival will be measured in months.
Overall survival will be measured in months.
Overall survival will be measured in months.
Overall survival will be measured in months.
|
3 years
|
|
Overall response rate
Time Frame: 2 years
|
According to RECIST criteria v1.1
|
2 years
|
|
Safety (assessed by toxicity grades defined by NCI-CTCAE (version 4.0)
Time Frame: 2 years
|
Safety as assessed by toxicity grades defined by NCI-CTCAE (version 4.0)
|
2 years
|
|
Quality of life (QoL)
Time Frame: 2 years
|
QoL measured by the FACT-G (version 4, Korean version)
|
2 years
|
|
Fatigue (FACIT-Fatigue scale (version 4, Korean version)
Time Frame: 2 years
|
Fatigue measured by the FACIT-Fatigue scale (version 4, Korean version)
|
2 years
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Jeong-Heum Baek, MD, Ph.D, Gachon University Gil Medical Center
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- Neoplasms
- Neoplasms by Site
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Colonic Diseases
- Intestinal Diseases
- Intestinal Neoplasms
- Rectal Diseases
- Neoplastic Processes
- Colorectal Neoplasms
- Neoplasm Metastasis
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Bevacizumab
- Curcumin
Other Study ID Numbers
Other Study ID Numbers
- GAIRB2015-87
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.